In the past few decades, it was discovered that the rate at which we age is strongly influenced by biochemical processes that, at least in animal models, can be controlled in the laboratory. Telomere shortening is one of these processes; another one is the ability of cells to detect nutrients mediated by the mTOR protein.
Researchers have been able to prolong life in many species by modifying either one of them. But what if we manipulate both? A team of researchers now studied it for the first time, with unexpected results. Blocking nutrient sensing by treatment with rapamycin, an mTOR inhibitor, delays the ageing of healthy mice but, curiously, it worsens diseases and premature ageing that occur in mice with short telomeres. This finding has important implications for the treatment of diseases associated with short telomeres, but also for age-related diseases that are also associated with short telomeres. The study is published in Nature Communications.
Telomeres, at the end of chromosomes, preserve the genetic information of the cells. They shorten with age until they can no longer fulfil their function: the cells stop dividing and the tissues age since they are no longer able to regenerate.
On the other hand, the ability of cells to detect nutrients depends on a cascade of biochemical signals that activates the mTOR protein. This is a fundamental molecular pathway because it controls the growth of cells and the whole organism. It also plays a central role in ageing: if the mTOR pathway is blocked, ageing slows down. But this had only been demonstrated in young and healthy mice. What happens when mice have short telomeres, associated with ageing and certain diseases called telomere syndromes?
An mTOR inhibitor is rapamycin, a drug that prolongs life in yeasts, flies, worms and mice, and that significantly reduces the incidence of cancer in mice with normal telomeres.
The researchers wanted to test whether rapamycin could also extend the life of mice with short telomeres, but they found that the opposite happens: they age up to 50% faster. This basic finding allowed the authors to discover that mTOR is, in fact, important for the survival of mice with short telomeres, and therefore blocking it has a negative effect.
But it also has clinical implications. Short telomeres are associated with or are the cause of the so-called telomere syndromes, diseases such as dyskeratosis congenita, aplastic anaemia, pulmonary and hepatic fibrosis, and other degenerative diseases for which few treatments exist. Blocking the mTOR pathway with rapamycin was considered a possible strategy against these diseases, but the results of the study suggest that it would not work and could even be harmful.
"In light of all the beneficial effects of inhibition of the mTOR pathway in extending longevity, here we set to address whether rapamycin treatment could also ameliorate the premature ageing phenotypes and the decreased lifespan of telomerase-deficient mice with short telomeres," the authors write. But, although "in control mice [with normal telomeres] rapamycin extended the lifespan, in mice with short telomeres it reduced it. We did not expect that. These results are of clinical interest for human diseases in which patients have critically short telomeres," explain authors of the paper.
Another surprise for the researchers was the finding that in mice with short telomeres the mTOR pathway is hyper-activated, that is, their cells are more sensitive than usual to the presence of nutrients. The authors interpret that it is precisely the greater ability to detect nutrients that allows these mice to survive, an unexpected conclusion that could open new avenues for research in the treatment of telomere syndromes.
"This discovery indicates that hyper-activation of the mTOR pathway is necessary to compensate for problems arising from having short telomeres," the senior author explains.
In fact, it is known that mTOR is also hyper-activated in some organs of elderly mice, which may indicate that this is a phenomenon associated not only with abnormally accelerated ageing but also with natural physiological ageing.
https://www.cnio.es/en/news/publications/rapamycin-has-harmful-effects-when-telomeres-are-short/
https://www.nature.com/articles/s41467-020-14962-1
http://sciencemission.com/site/index.php?page=news&type=view&id=publications%2Fthe-mtor-pathway-is&filter=22
Rapamycin has harmful effects when telomeres are short
- 1,547 views
- Added
Edited
Latest News
Mechanism of sugar signalin…
By newseditor
Posted 19 May
How does the brain turn wav…
By newseditor
Posted 19 May
A trial HIV vaccine trigger…
By newseditor
Posted 19 May
AI to predict DNA methylati…
By newseditor
Posted 19 May
Hyperactive platelets from…
By newseditor
Posted 19 May
Other Top Stories
Culturing human placenta stem cells for first time
Read more
Another protein preventing synapse elimination identified
Read more
Direct link between glands and implanting embryos critical to pregn…
Read more
How the brain tells our limbs apart
Read more
Extending egg health with age
Read more
Protocols
Breast cancer-on-chip for p…
By newseditor
Posted 16 May
Methods for making and obse…
By newseditor
Posted 15 May
Mime-seq 2.0: a method to s…
By newseditor
Posted 13 May
Improved detection of DNA r…
By newseditor
Posted 09 May
Single-cell adhesive profil…
By newseditor
Posted 07 May
Publications
Molecular mechanism of treh…
By newseditor
Posted 19 May
Hue selectivity from recurr…
By newseditor
Posted 19 May
Vaccine induction of hetero…
By newseditor
Posted 19 May
Brain border-associated mac…
By newseditor
Posted 19 May
Inhibition of fatty acid up…
By newseditor
Posted 19 May
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar